Ocular Therapeutix has initiated a long-term extension trial evaluating the investigational intravitreal therapy AXPAXLI in ...

Scaling vision correction across the global textile and garment sector was estimated to generate $27B in incremental annual ...

A rolling NDA has been initiated for tinlarebant in STGD1, potentially positioning the first disease-modifying systemic ...

Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies ...

Eyecelerator, a partner of the American Academy of Ophthalmology, is self-described as having the goal of advancing eye care ...

Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, ...

Glaukos Corporation announced that the US Centers for Medicare and Medicaid Services (CMS) has assigned a permanent ...

Preoperative identification and eradication of Demodex can improve ocular-surface comfort and may mitigate cataract-surgery ...

Propensity-matched analyses showed smokers had significantly higher risk across all studied ocular outcomes over 10 years, ...

Self-reported hearing impairment reduced the likelihood of achieving clinically meaningful functional improvement after ...

New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may ...

Gabriel discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the ...